18 March, 2025 16:47:57 IST 
Speciality chemicals start-up, Scimplify, has announced a $40-mn ‘Series B’ funding round to scale its novel working model that is seeking to how speciality chemicals are developed, manufactured, and distributed worldwide.
Scimplify focusses on the entire value chain of research and development (R&D), manufacturing and distribution of chemicals. It has built relationships with more than 200 chemicals manufacturers based in low-cost regions like Asia and deploys their capabilities to fulfil the orders it receives from customers globally. The company caters to companies across pharmaceuticals, agrochemicals, industrial chemicals, flavours & fragrances, food & nutrition, beauty & personal care, among others.
The $40-mn series B funding round was co-led by Accel and Bertelsmann with participation from UMI and existing investors including Omnivore and 3one4 Capital. This latest round brings Scimplify’s total funding to $54-mn, following $13.5-mn raised across seed and Series A rounds earlier.
The company said the investment will help boost its international growth, “with exports currently reaching 16 countries and plans to aggressively expand both geographically and into new industry segments”.
Founded in mid-2023, the company’s co-founders include Salil Srivastava, Sachin Santhosh, and Dheeraj Dhingra. The company’s “full-stack solution” platform combines in-house scientific expertise with the network of manufacturing plants across low-cost regions.
“This creates a true ‘plug and play’ alternative to traditional manufacturing - customers simply bring their chemical needs, and Scimplify handles everything from R&D to specialised production, leveraging the perfect manufacturing partner for each specific chemistry without the capital investment or operational complexity of traditional approaches,” the company informed.
“For decades, speciality chemical manufacturers have invested millions in facilities that can only produce a handful of compounds, often running at partial capacity while lacking R&D capabilities. This creates a paradox: excess capacity alongside supply shortages. We’ve flipped this model, connecting our scientific teams with hundreds of manufacturing plants to create a responsive ecosystem that can adapt as market needs shift,” said Mr. Santhosh.
The impact of Scimplify’s approach is being felt immediately, he said. “US customers previously locked into Chinese supply chains for critical specialty chemicals are now accessing superior alternatives from India without the headaches of establishing ground teams or navigating complex onboarding processes,” he informed.
According to Scimplify, it scores over traditional manufacturers with its speed and flexibility. “While competitors remain anchored to fixed assets and limited chemistries, Scimplify can rapidly pivot across different chemical processes and scale production based on real-time customer needs. Their R&D capabilities provide expertise typically inaccessible to individual manufacturers, allowing them to solve complex chemical challenges that others simply cannot address,” it added.
